1
|
Ruffier A, Pointreau Y, Sacier V, Balavoine M, Lamrani-Ghaouti A, Guihard S, Rivera S. [Clinical research in private sector: Which strategic analysis?]. Cancer Radiother 2023; 27:469-473. [PMID: 37596122 DOI: 10.1016/j.canrad.2023.06.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2023] [Revised: 06/22/2023] [Accepted: 06/23/2023] [Indexed: 08/20/2023]
Abstract
Clinical research in private practice has significantly increased in recent years and has become crucial for the attractiveness of centres both for patients who can access innovative treatments and molecules and for participating physicians. The responsiveness, the size and reduced number of interlocutors, flexibility, and decision-making autonomy of private practitioners are strengths in the strategic analysis of clinical research in the private sector. However, the varied medical activity allowing for broader recruitment, location of practice, and administrative time related leadership roles can become weakness in terms of quality and time dedicated to this research activity, which still relies heavily on strong individual involvement. Collaborations, which develop when clinical research in private centres is dynamic, are sources of opportunities, growth, and progress, allowing participation in various ambitious projects that can benefit patients in these facilities. Recent administrative and legislative complexities for trial integration and competition with academic structures can threaten this important clinical research activity for private practices, requiring reflection on its valorisation and promotion to ensure its sustainability.
Collapse
Affiliation(s)
- A Ruffier
- Centre Jean-Bernard, institut inter-régional de cancérologie (ILC), CCS, 64, rue de Degré, 72000 Le Mans, France; Sorecoh, centre Jean-Bernard, 64, rue de Degré, 72000 Le Mans, France; WeProm, centre Jean-Bernard, 64, rue de Degré, 72000 Le Mans, France.
| | - Y Pointreau
- Centre Jean-Bernard, institut inter-régional de cancérologie (ILC), CCS, 64, rue de Degré, 72000 Le Mans, France; Sorecoh, centre Jean-Bernard, 64, rue de Degré, 72000 Le Mans, France; WeProm, centre Jean-Bernard, 64, rue de Degré, 72000 Le Mans, France
| | - V Sacier
- Centre Jean-Bernard, institut inter-régional de cancérologie (ILC), CCS, 64, rue de Degré, 72000 Le Mans, France; Sorecoh, centre Jean-Bernard, 64, rue de Degré, 72000 Le Mans, France
| | - M Balavoine
- Centre Jean-Bernard, institut inter-régional de cancérologie (ILC), CCS, 64, rue de Degré, 72000 Le Mans, France; WeProm, centre Jean-Bernard, 64, rue de Degré, 72000 Le Mans, France
| | | | - S Guihard
- Institut de cancérologie de Strasbourg (ICANS), 17, rue Albert-Calmette, BP 2305, 67033 Strasbourg, France
| | - S Rivera
- Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif, France
| |
Collapse
|
2
|
Guihard S, Piot M, Issoufaly I, Giraud P, Bruand M, Faivre JC, Eugène R, Liem X, Pasquier D, Lamrani-Ghaouti A, Ghannam Y, Ruffier A, Guilbert P, Larnaudie A, Thariat J, Rivera S, Clavier JB. [Real world data in radiotherapy: A data farming project by Unitrad]. Cancer Radiother 2023; 27:455-459. [PMID: 37517975 DOI: 10.1016/j.canrad.2023.06.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Accepted: 06/16/2023] [Indexed: 08/01/2023]
Abstract
The aim of the data farming project by the Unitrad group is to produce and use large quantities of structured real-life data throughout radiotherapy treatment. Starting in 2016, target real world data were selected at expert consensus conferences and regularly updated, then captured in MOSAIQ© as the patient was treated. For each partner institution, the data was then stored in a relational database, then extracted and used by researchers to create real world knowledge. This production was carried out in a multicentre, coordinated fashion. When necessary, the raw data was shared according to the research projects, in compliance with regulations. Feedack was provided at each stage, enabling the system to evolve flexibly and rapidly, using the "agile" method. This work, which is constantly evolving, has led to the creation of health data warehouses focused on data of interest in radiotherapy, and the publication of numerous academic studies. It forms part of the wider context of the exploitation of real-life data in cancerology. Unitrad data farming is a collaborative project for creating knowledge from real-life radiotherapy data, based on an active network of clinicians and researchers.
Collapse
Affiliation(s)
- S Guihard
- Radiothérapie, institut de cancérologie de Strasbourg (ICANS), 17, rue Albert-Calmette, BP 23025, 67033 Strasbourg, France.
| | - M Piot
- Laboratoire List3N, école doctorale SPI de l'université de technologie de Troyes, 12, rue Marie-Curie, 10300 Troyes, France
| | - I Issoufaly
- Radiothérapie, Gustave-Roussy, Villejuif, France
| | - P Giraud
- Inserm, UMR 1138, équipe« Science de l'information au service de la médecine », 15, rue de l'École-de-Médecine, 75006 Paris, France; Radiothérapie, hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - M Bruand
- Radiothérapie, Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy, France
| | - J-C Faivre
- Radiothérapie, Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy, France
| | - R Eugène
- Oncology Informatics Consultant, Elekta SAS, Boulogne-Billancourt, France
| | - X Liem
- Radiothérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, 59000 Lille, France
| | - D Pasquier
- Radiothérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, 59000 Lille, France
| | | | - Y Ghannam
- Radiothérapie, Gustave-Roussy, Villejuif, France
| | - A Ruffier
- Radiothérapie, institut interrégional de cancérologie, centre Jean-Bernard, clinique Victor-Hugo, Le Mans, France
| | - P Guilbert
- Radiothérapie, institut Godinot, 1, rue du Général-Koenig, 51100 Reims, France
| | - A Larnaudie
- Radiothérapie, centre François-Baclesse, 14000 Caen, France
| | - J Thariat
- Radiothérapie, centre François-Baclesse, 14000 Caen, France
| | - S Rivera
- Radiothérapie, Gustave-Roussy, Villejuif, France
| | - J-B Clavier
- Radiothérapie, institut de cancérologie de Strasbourg (ICANS), 17, rue Albert-Calmette, BP 23025, 67033 Strasbourg, France
| |
Collapse
|
3
|
Castelli J, Benezery K, Hasbini A, Gery B, Berger A, Liem X, Guihard S, Chapet S, Thureau S, Auberdiac P, Pommier P, Thariat J, Campillo B, de Crevoisier R. OC-0831 Results of ARTIX phase III study: adaptive radiotherapy versus standard IMRT in head and neck cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02695-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
4
|
Droff N, Clavier JB, Brahimi Y, Keller A, Vigneron C, Eugène R, Guihard S. Description monocentrique de la toxicité aiguë et tardive des irradiations mammaires par une technique de Tomodirect et comparaison avec des techniques de radiothérapie tridimensionnelle et d’autres radiothérapies conformationnelles avec modulation d’intensité par une méthode de data farming. Cancer Radiother 2021. [DOI: 10.1016/j.canrad.2021.07.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Khalladi N, Dejean C, Bosset M, Pointreau Y, Kinj R, Racadot S, Castelli J, Huguet F, Renard S, Guihard S, Tao Y, Rouvier JM, Johnson A, Bourhis J, Xu Shan S, Thariat J. A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients. Cancer Radiother 2021; 25:755-762. [PMID: 34565664 DOI: 10.1016/j.canrad.2021.04.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Revised: 04/19/2021] [Accepted: 04/28/2021] [Indexed: 11/25/2022]
Abstract
PURPOSE A Benchmark Case (BC) was performed as part of the quality assurance process of the randomized phase 2 GORTEC 2014-14 OMET study, testing the possibility of multisite stereotactic radiation therapy (SBRT) alone in oligometastatic head and neck squamous cell carcinoma (HNSCC) as an alternative to systemic treatment and SBRT. MATERIAL AND METHODS Compliance of the investigating centers with the prescription, delineation, planning and evaluation recommendations available in the research protocol was assessed. In addition, classical dosimetric analysis was supplemented by quantitative geometric analysis using conformation indices. RESULTS Twenty centers participated in the BC analysis. Among them, four major deviations (MaD) were reported in two centers. Two (10%) centers in MaD had omitted the satellite tumor nodule and secondarily validated after revision. Their respective DICE indexes were 0.37 and 0 and use of extracranial SBRT devices suboptimal There were significant residual heterogeneities between participating centers, including those with a similar SBRT equipment, with impact of plan quality using standard indicators and geometric indices. CONCLUSION A priori QA using a BC conditioning the participation of the clinical investigation centers showed deviations from good SBRT practice and led to the exclusion of one out of the twenty participating centers. The majority of centers have demonstrated rigorous compliance with the research protocol. The use of quality indexes adds a complementary approach to improve assessment of plan quality.
Collapse
Affiliation(s)
- N Khalladi
- Centre François Baclesse, 3, avenue General Harris, 14076 Caen, France
| | - C Dejean
- Centre Antoine Lacassagne, Nice, France
| | - M Bosset
- Centre Marie Curie, Valence, France
| | | | - R Kinj
- Centre Antoine Lacassagne, Nice, France
| | | | | | - F Huguet
- Centre hospitalier et universitaire Tenon, Paris, France
| | - S Renard
- Institut de Cancérologie de Lorraine, Nancy, France
| | - S Guihard
- Institut de Cancérologie Strasbourg Europe, Strasbourg, France
| | - Y Tao
- Institut Gustave Roussy, Villejuif, France
| | - J M Rouvier
- Centre hospitalier régional et universitaire, Besançon-Montbéliard, France
| | - A Johnson
- Centre François Baclesse, 3, avenue General Harris, 14076 Caen, France
| | - J Bourhis
- Centre hospitalier universitaire vaudois, Lausanne, Switzerland
| | - S Xu Shan
- Centre hospitalier universitaire vaudois, Lausanne, Switzerland
| | - J Thariat
- Centre François Baclesse, 3, avenue General Harris, 14076 Caen, France; Corpuscular Physics Laboratory-Normandy University, Caen, France.
| |
Collapse
|
6
|
Leleu T, Bastit V, Doré M, Kammerer E, Florescu C, Alfonsi M, Troussier I, Bensadoun RJ, Biau J, Blais E, Coutte A, Deberne M, Wiazzane N, Dupin C, Faivre JC, Giraud P, Graff P, Guihard S, Huguet F, Janoray G, Liem X, Pointreau Y, Racadot S, Schick U, Servagi-Vernat S, Sun XS, Thureau S, Villa J, Vulquin N, Wong S, Patron V, Thariat J. Histosurgical mapping of endoscopic endonasal surgery of sinonasal tumours to improve radiotherapy guidance. Cancer Radiother 2021; 26:440-444. [PMID: 34175228 DOI: 10.1016/j.canrad.2021.06.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 05/21/2021] [Accepted: 06/01/2021] [Indexed: 11/27/2022]
Abstract
PURPOSE Endoscopic endonasal surgery (EES) is becoming a standard for most malignant sinonasal tumours. Margin analysis after piecemeal resection is complex and optimally relies on accurate histosurgical mapping. Postoperative radiotherapy may be adapted based on margin assessment mapping to reduce the dose to some sinonasal subvolumes. We assessed the use of histosurgical mapping by radiation oncologists (RO). MATERIAL AND METHODS A French practice survey was performed across 29 ENT expert RO (2 did not answer) regarding integration of information on EES, as well as quality of operative and pathology reportsto refine radiotherapy planning after EES. This was assessed through an electronic questionnaire. RESULTS EES was ubiquitously performed in France. Operative and pathology reports yielded accurate description of EES samples according to 66.7% of interviewed RO. Accuracy of margin assessment was however insufficient according to more than 40.0% of RO. Additional margins/biopsies of the operative bed were available in 55.2% (16/29) of the centres. In the absence of additional margins, quality of resection after EES was considered as microscopically incomplete in 48.3% or dubious in 48.3% of RO. As performed, histosurgical mapping allowed radiotherapy dose and volumes adaptation according to 26.3% of RO only. CONCLUSIONS Standardized histosurgical mapping with margin and additional margin analysis could be more systematic. Advantages of accurate EES reporting could be dose painting radiotherapy to further decrease morbidity in sinonasal tumours.
Collapse
Affiliation(s)
- T Leleu
- Department of radiation oncology, centre François-Baclesse, Caen, France
| | - V Bastit
- Department of surgery, centre François-Baclesse, Caen, France
| | | | - E Kammerer
- Department of radiation oncology, centre François-Baclesse, Caen, France
| | - C Florescu
- Department of radiation oncology, centre François-Baclesse, Caen, France
| | | | | | | | - J Biau
- CJP, Clermont-Ferrand, France
| | - E Blais
- AP-HP, Pitié-Salpêtrière, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - X S Sun
- CHU, Besançon Montbéliard, France
| | | | | | | | | | - V Patron
- Department of ENT surgery, CHU Caen, Caen, France
| | - J Thariat
- Department of radiation oncology, centre François-Baclesse, Caen, France; Unicaen, Normandie Université, Caen, France; GORTEC, France.
| |
Collapse
|
7
|
Issoufaly I, Petit C, Guihard S, Eugene R, Jung L, Clavier J, Servagi Vernat S, Bellefquih S, Rivera S. Normo Versus Hypofractionated Whole Breast Radiation-Related Acute Toxicities: Evolution over Time in Systematic Multicentric Real Life Data. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
8
|
Guihard S, Petit C, Clavier J, Jung L, Vernat SS, Bellefquih S, Ruffier A, Brusadin G, Remi E, Rivera S. PH-0598: Normo versus hypofractionated whole breast irradiation: Are real life data what we expect? Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00620-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Issoufaly I, Rivera S, Guihard S, Clavier J, Rémi E, Vigneron C, Menoux I, Mazzara C, Servagi Vernat S, Bellefquih S, Petit C. Comparaison intercentre de la toxicité aiguë de 2052 patientes après radiothérapie mammaire normo- ou hypofractionnée à partir d’une fiche standardisée d’évaluation. Cancer Radiother 2020. [DOI: 10.1016/j.canrad.2020.08.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Clavier J, Jung L, Eugène R, Mazzara C, Servagi S, Rivera S, Issoufaly I, Bellefqih S, Hannoun-Lévi JM, Petit C, Feuillade J, Fontbonne JM, Bonnet N, Jou A, Piot M, Liem X, Thariat J, Guihard S. Capture, restitution et exploitation multicentrique des données de vie réelle en radiothérapie. Cancer Radiother 2020. [DOI: 10.1016/j.canrad.2020.08.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Bibault JE, Denis F, Guihard S, Clavier JB, Durdux C, Giraud P, Kreps S, Maaradji S, Dautruche A, Fabiano E, Feutren T, Thariat J. [New concepts of medical consultation in oncology]. Cancer Radiother 2020; 24:751-754. [PMID: 32753236 PMCID: PMC7395590 DOI: 10.1016/j.canrad.2020.05.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2020] [Revised: 05/04/2020] [Accepted: 05/07/2020] [Indexed: 12/27/2022]
Abstract
New concepts of medical consultations are currently disrupting the practice of medicine. The use of standardized questionnaires, or patient-reported outcome (PRO and ePRO) has already significantly changed the relationship between the physician and the patient. Telemedicine, or even automatic conversational agents, such as chatbots, are also providing more convenient access to care and medical information for many patients. These tools have a major impact in oncology, precisely because of the rising chronicity of the diseases the radiation oncologists treat. In this article, we provide a detailed analysis of these new concepts.
Collapse
Affiliation(s)
- J-E Bibault
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, Paris, France; Université de Paris, 85, boulevard Saint-Germain, 75006 Paris, France; Inserm, UMR 1138, équipe « science de l'information au service de la médecine », 15, rue de l'École-de-Médecine, 75006 Paris, France.
| | - F Denis
- Institut inter-régional de cancérologie Jean-Bernard, 9, rue Beauverger, 72100 Le Mans, France
| | - S Guihard
- Département de radiothérapie, institut de cancérologie Strasbourg-Europe, 17, rue Albert-Calmette, 67200 Strasbourg, France; Inserm, UMR 1113, équipe « Réponse au stress et thérapies innovantes », 3, avenue Molière, 67200 Strasbourg, France
| | - J-B Clavier
- Institut inter-régional de cancérologie Jean-Bernard, 9, rue Beauverger, 72100 Le Mans, France
| | - C Durdux
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, Paris, France; Université de Paris, 85, boulevard Saint-Germain, 75006 Paris, France
| | - P Giraud
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, Paris, France; Université de Paris, 85, boulevard Saint-Germain, 75006 Paris, France
| | - S Kreps
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, Paris, France; Université de Paris, 85, boulevard Saint-Germain, 75006 Paris, France
| | - S Maaradji
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, Paris, France; Université de Paris, 85, boulevard Saint-Germain, 75006 Paris, France
| | - A Dautruche
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, Paris, France; Université de Paris, 85, boulevard Saint-Germain, 75006 Paris, France
| | - E Fabiano
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, Paris, France; Université de Paris, 85, boulevard Saint-Germain, 75006 Paris, France
| | - T Feutren
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, Paris, France; Université de Paris, 85, boulevard Saint-Germain, 75006 Paris, France
| | - J Thariat
- Département de radiothérapie, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France; Association advance resource centre for hadrontherapy in Europe (Archade), 3, avenue General-Harris, 14000 Caen, France; Laboratoire de physique corpusculaire, Institut national de physique nucléaire et de physique des particules (IN2P3), 6, boulevard Maréchal-Juin, 14000 Caen, France; École nationale supérieure d'ingénieurs de Caen (Ensicaen), 6, boulevard Maréchal-Juin, 14000 Caen, France; UMR6534, Unicaen, Normandie université, 3, avenue General-Harris, 14000 Caen, France
| |
Collapse
|
12
|
Boyer T, Gonzales F, Barthélémy A, Marceau-Renaut A, Peyrouze P, Guihard S, Lepelley P, Plesa A, Nibourel O, Delattre C, Wetterwald M, Pottier N, Plantier I, Botton SD, Dombret H, Berthon C, Preudhomme C, Roumier C, Cheok M. Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study. Cancers (Basel) 2019; 11:cancers11091323. [PMID: 31500210 PMCID: PMC6770064 DOI: 10.3390/cancers11091323] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Revised: 08/23/2019] [Accepted: 09/03/2019] [Indexed: 11/16/2022] Open
Abstract
ABCB1 is a member of the ATP binding cassette transporter family and high ABCB1 activity is considered as a poor prognostic factor in acute myeloid leukemia (AML) treated with intensive chemotherapy, its direct relation with drug resistance remains unclear. We evaluated ABCB1 activity in relation with clinical parameters and treatment response to standard chemotherapy in 321 patients with de novo AML. We assessed multiple clinical relationships of ABCB1 activity—ex vivo drug resistance, gene expression, and the ABCB1 inhibitor quinine were evaluated. ABCB1 activity was observed in 58% of AML and was linked to low white blood cell count, high expression of CD34, absence of FLT3-ITD, and absence of mutant NPM1. Moreover, ABCB1 activity was associated with worse overall- and event-free survival. However, ABCB1 activity did not directly lead to ex vivo drug resistance to anthracyclines. We found that ABCB1 was highly correlated with gene expressions of BAALC, CD34, CD200, and CD7, indicating that ABCB1 expression maybe a passenger characteristic of high-risk AML. Furthermore, ABCB1 was inversely correlated to HOX cluster genes and CD33. Thus, low ABCB1 AML patients benefited specifically from anti-CD33 treatment by gemtuzumab ozogamicin in addition to standard chemotherapy. We showed prognostic importance of ABCB1 gene expression, protein expression, and activity. Furthermore, ABCB1 was not directly linked to drug resistance, ABCB1 inhibition did not improve outcome of high ABCB1 AML patients and thus high ABCB1 may represent a passenger characteristic of high-risk AML.
Collapse
Affiliation(s)
- Thomas Boyer
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Fanny Gonzales
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Adeline Barthélémy
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Alice Marceau-Renaut
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Pauline Peyrouze
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Soizic Guihard
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Pascale Lepelley
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Adriana Plesa
- Laboratory of Hematology, Hospital of Lyon-South, 69495 Pierre - Benite, France
| | - Olivier Nibourel
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Carole Delattre
- Laboratory of Hematology, Hospital of Dunkerque, 59240 Dunkerque, France
| | - Marc Wetterwald
- Department of Hematological Diseases, Hospital of Dunkerque, 59240 Dunkerque, France
| | - Nicolas Pottier
- Department of Biochemistry, University Hospital Lille, 59000 Lille, France
| | - Isabelle Plantier
- Department of Hematological Diseases, Hospital of Roubaix, 59100 Roubaix, France
| | - Stéphane de Botton
- Department of Clinical Hematology, Gustave Roussy Institute, 94800 Paris, France
| | - Hervé Dombret
- Department of Hematology, University Paris 7, 75013 Paris, France
| | - Céline Berthon
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
- Department of Hematological Diseases, University Hospital of Lille, 59000 Lille, France
| | - Claude Preudhomme
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Christophe Roumier
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Meyling Cheok
- Laboratory of Hematology, CHU Lille, 59000 Lille, France.
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France.
| |
Collapse
|
13
|
Clavier J, Eugene R, Thariat J, Antoni D, Beneyton V, Claude L, Fontbonne J, Gaillot N, Ganansia V, Jamain C, Lepinoy A, Laude C, Mazzara C, Noblet C, Racadot S, Ruffier A, Servagi S, Truntzer P, Guihard S. EP-1662 Multicentric structured medical data production on an OIS for modeling of radiotherapy effects. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32082-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
14
|
Beddok A, Faivre J, Coutte A, Le Guévelou J, Welmant J, Clavier J, Guihard S, Janoray G, Calugaru V, Pointreau Y, Lacout A, Salleron J, Lefranc M, Hasboun D, Duvernoy H, Thariat J. PO-0754 Radiation-induced nausea and vomiting: how to delineate the Dorsal Vagal Complex ? Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31174-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Guihard S, Eugène R, Thariat J, Beneyton V, Claude L, Fontbonne JM, Gaillot N, Ganansia V, Jamain C, Lepinoy A, Laude C, Mazzara C, Racadot S, Ruffier A, Servagi S, Truntzer P, Clavier J. Dossier structuré commun de radiothérapie basé sur Mosaiq®. Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
16
|
Le Fèvre C, Antoni D, Thiéry A, Keller A, Truntzer P, Vigneron C, Clavier JB, Guihard S, Pop M, Schumacher C, Salze P, Noël G. [Radiotherapy of bone metastases in France: A descriptive monocentric retrospective study]. Cancer Radiother 2018; 22:148-162. [PMID: 29602695 DOI: 10.1016/j.canrad.2017.09.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Revised: 08/03/2017] [Accepted: 09/08/2017] [Indexed: 11/24/2022]
Abstract
PURPOSE Bone metastases cause pain and affect patients' quality of life. Radiation therapy is one of the reference analgesic treatments. The objective of this study was to compare the current practices of a French radiotherapy department for the treatment of uncomplicated bone metastases with data from the literature in order to improve and optimize the management of patients. MATERIAL AND METHODS A retrospective monocentric study of patients who underwent palliative irradiation of uncomplicated bone metastases was performed. RESULTS Ninety-one patients had 116 treatments of uncomplicated bone metastases between January 2014 and December 2015, including 44 men (48%) and 47 women (52%) with an average age of 63years (25-88years). Primary tumours most commonly found were breast cancer (35%), lung cancer (16%) and prostate cancer (12%). The regimens used were in 29% of cases 30Gy in ten fractions (group 30Gy), in 21% of cases 20Gy in five fractions (group 20Gy), in 22% of cases 8Gy in one fraction (group 8Gy) and in 28% of cases 23.31Gy in three fractions of stereotactic body irradiation (stereotactic group). The general condition of the patient (P<0.001), pain score and analgesic (P<0.001), oligometastatic profile (P=0.003) and practitioner experience (P<0.001) were factors influencing the choice of the regimen irradiation. Age (P=0.46), sex (P=0.14), anticancer treatments (P=0.56), concomitant hospitalization (P=0.14) and the distance between the radiotherapy centre and home (P=0.87) did not influence the decision significantly. A total of three cases of spinal compression and one case of post-therapeutic fracture were observed, occurring between one and 128days and 577days after irradiation, respectively. Eight percent of all irradiated metastases were reirradiated with a delay ranging between 13 and 434days after the first irradiation. The re-irradiation rate was significantly higher after 8Gy (P=0.02). The rate of death was significantly lower in the stereotactic arm (P<0.001) and overall survival was significantly greater in the stereotactic arm (P<0.001). CONCLUSION This study showed that patients' analysed was comparable to the population of different studies. Predictive factors for the choice of the treatment regimen were identified. Non-fractionnated therapy was underutilised while stereotactic treatment was increasingly prescribed, showing an evolution in the management of patients.
Collapse
Affiliation(s)
- C Le Fèvre
- Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - D Antoni
- Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France; Laboratoire EA 3430, Fédération de médecine translationnelle de Strasbourg (FMTS), université de Strasbourg, 67000 Strasbourg, France
| | - A Thiéry
- Département de santé publique, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - A Keller
- Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - P Truntzer
- Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - C Vigneron
- Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - J-B Clavier
- Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - S Guihard
- Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - M Pop
- Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - C Schumacher
- Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - P Salze
- Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - G Noël
- Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France; Laboratoire EA 3430, Fédération de médecine translationnelle de Strasbourg (FMTS), université de Strasbourg, 67000 Strasbourg, France.
| |
Collapse
|
17
|
Boyer T, Gonzales F, Plesa A, Peyrouze P, Barthelemy A, Guihard S, Quesnel B, Roumier C, Preudhomme C, Cheok M. Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up. J Vis Exp 2018. [PMID: 29630051 DOI: 10.3791/56976] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Acute myeloid leukemia (AML) is a heterogeneous, and if not treated, fatal disease. It is the most common cause of leukemia-associated mortality in adults. Initially, AML is a disease of hematopoietic stem cells (HSC) characterized by arrest of differentiation, subsequent accumulation of leukemia blast cells, and reduced production of functional hematopoietic elements. Heterogeneity extends to the presence of leukemia stem cells (LSC), with this dynamic cell compartment evolving to overcome various selection pressures imposed upon during leukemia progression and treatment. To further define the LSC population, the addition of CD90 and CD45RA allows the discrimination of normal HSCs and multipotent progenitors within the CD34+CD38- cell compartment. Here, we outline a protocol to detect simultaneous expression of several putative LSC markers (CD34, CD38, CD45RA, CD90) on primary blast cells of human AML by multiparametric flow cytometry. Furthermore, we show how to quantify three progenitor populations and a putative LSC population with increasing degree of maturation. We confirmed the presence of these populations in corresponding patient-derived-xenografts. This method of detection and quantification of putative LSC may be used for clinical follow-up of chemotherapy response (i.e., minimal residual disease), as residual LSC may cause AML relapse.
Collapse
Affiliation(s)
- Thomas Boyer
- Laboratoire d'hématologie, CHU Lille; Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer
| | - Fanny Gonzales
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer; Service d'hématologie pédiatrique, hôpital Jeanne de Flandre, CHU Lille
| | | | - Pauline Peyrouze
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer
| | - Adeline Barthelemy
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer
| | - Soizic Guihard
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer
| | - Bruno Quesnel
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer; Service des Maladies du Sang, hôpital Claude Huriez, CHU Lille
| | - Christophe Roumier
- Laboratoire d'hématologie, CHU Lille; Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer
| | - Claude Preudhomme
- Laboratoire d'hématologie, CHU Lille; Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer
| | - Meyling Cheok
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer;
| |
Collapse
|
18
|
Ohnleiter T, Truntzer P, Antoni D, Guihard S, Elgard AM, Noël G. Facteurs pronostiques de la ré-irradiation des cancers des voies aérodigestives supérieures : revue de la littérature. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
19
|
Ohnleiter T, Truntzer P, Antoni D, Guihard S, Elgard AM, Noël G. Facteurs pronostiques de la ré-irradiation des cancers des voies aérodigestives supérieures : revue de la littérature. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.04.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
20
|
Menoux I, Guihard S, Antoni D, Bijon JC, Noël G. [Choroidal metastasis from a lung adenocarcinoma treated by intravitreal injection of anti-VEGF and external beam radiotherapy: A case report]. Cancer Radiother 2017; 21:130-133. [PMID: 28343900 DOI: 10.1016/j.canrad.2016.09.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2015] [Revised: 04/19/2016] [Accepted: 09/21/2016] [Indexed: 11/20/2022]
Abstract
Choroidal metastases of lung cancer are very uncommon. This localization should be suspected on blurred vision and confirmed with an ophthalmological examination. Its treatment is not entirely codified. We report a case of blurred vision secondary to bilateral choroidal metastasis in a patient with choroidal metastases from a lung adenocarcinoma, treated by intravitreal anti-vascular endothelial growth factor (VEGF) injection and external beam radiotherapy. According to a literature review, we analyzed the place of the targeted treatments used alone or combined with the radiotherapy.
Collapse
Affiliation(s)
- I Menoux
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France
| | - S Guihard
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France
| | - D Antoni
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France; Fédération de médecine translationnelle de Strasbourg (FMTS), laboratoire de radiobiologie, EA 3430, université de Strasbourg, 67065 Strasbourg, France
| | - J-C Bijon
- Cabinet d'ophtalmologie, 7 bis, rue de l'Hôpital, 67600 Sélestat, France
| | - G Noël
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France; Fédération de médecine translationnelle de Strasbourg (FMTS), laboratoire de radiobiologie, EA 3430, université de Strasbourg, 67065 Strasbourg, France.
| |
Collapse
|
21
|
Rouers M, Antoni D, Bornert F, Wong CL, Dubourg S, Truntzer P, Qiu H, Thompson A, Bourrier C, Meyer P, Guihard S, Noel G. Ability to Deliver Safe Dental Care and Optimal Prosthetic Rehabilitation Are Correlating With Irradiation Doses in Maxillary and Mandible. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Antoni D, Pop M, Truntzer P, Rieger E, Salze P, Clavier J, Guihard S, Bauer N, Vigneron C, Velten M, Noel G. Impact of a Specific One-on-One Announcement Procedure Provided by a Radiation Therapist Before Radiation Therapy: Results of a Prospective Randomized Controlled Trial. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Nibourel O, Guihard S, Roumier C, Pottier N, Terre C, Paquet A, Peyrouze P, Geffroy S, Quentin S, Alberdi A, Abdelali RB, Renneville A, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH. Copy-number analysis identified new prognostic marker in acute myeloid leukemia. Leukemia 2016; 31:555-564. [PMID: 27686867 DOI: 10.1038/leu.2016.265] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Revised: 08/18/2016] [Accepted: 08/24/2016] [Indexed: 01/08/2023]
Abstract
Recent advances in genomic technologies have revolutionized acute myeloid leukemia (AML) understanding by identifying potential novel actionable genomic alterations. Consequently, current risk stratification at diagnosis not only relies on cytogenetics, but also on the inclusion of several of these abnormalities. Despite this progress, AML remains a heterogeneous and complex malignancy with variable response to current therapy. Although copy-number alterations (CNAs) are accepted prognostic markers in cancers, large-scale genomic studies aiming at identifying specific prognostic CNA-based markers in AML are still lacking. Using 367 AML, we identified four recurrent CNA on chromosomes 11 and 21 that predicted outcome even after adjusting for standard prognostic risk factors and potentially delineated two new subclasses of AML with poor prognosis. ERG amplification, the most frequent CNA, was related to cytarabine resistance, a cornerstone drug of AML therapy. These findings were further validated in The Cancer Genome Atlas data. Our results demonstrate that specific CNA are of independent prognostic relevance, and provide new molecular information into the genomic basis of AML and cytarabine response. Finally, these CNA identified two potential novel risk groups of AML, which when confirmed prospectively, may improve the clinical risk stratification and potentially the AML outcome.
Collapse
Affiliation(s)
- O Nibourel
- CHU Lille University Hospital, Department of Hematology, Lille, France
| | - S Guihard
- INSERM UMR-S1172, Institute for Cancer Research of Lille, Factors of Leukemia Cell Persistance, Lille Cedex, France
| | - C Roumier
- CHU Lille University Hospital, Department of Hematology, Lille, France
| | - N Pottier
- CHU Lille University Hospital, Department of Biochemistry and Molecular Biology, Lille, France
| | - C Terre
- Hospital of Versailles, Department of Hematology, Chesnay, France
| | - A Paquet
- University Côte d'Azur, CNRS Institute of Molecular and Cellular Pharmacology, Sophia-Antipolis, Nice, France
| | - P Peyrouze
- INSERM UMR-S1172, Institute for Cancer Research of Lille, Factors of Leukemia Cell Persistance, Lille Cedex, France
| | - S Geffroy
- CHU Lille University Hospital, Department of Hematology, Lille, France
| | - S Quentin
- University Paris Diderot, INSERM U944 Saint-Louis Hospital, Department of Hematology, Paris, France
| | - A Alberdi
- University Paris Diderot, INSERM U944 Saint-Louis Hospital, Department of Hematology, Paris, France
| | - R B Abdelali
- University Paris Diderot, INSERM U944 Saint-Louis Hospital, Department of Hematology, Paris, France
| | - A Renneville
- CHU Lille University Hospital, Department of Hematology, Lille, France
| | - C Demay
- CHU Lille University Hospital, Department of Hematology, Lille, France
| | - K Celli-Lebras
- University Paris 7, Department of Hematology, Paris, France
| | - P Barbry
- University Côte d'Azur, CNRS Institute of Molecular and Cellular Pharmacology, Sophia-Antipolis, Nice, France
| | - B Quesnel
- INSERM UMR-S1172, Institute for Cancer Research of Lille, Factors of Leukemia Cell Persistance, Lille Cedex, France
| | - S Castaigne
- Hospital of Versailles, Department of Hematology, Chesnay, France
| | - H Dombret
- University Paris 7, Department of Hematology, Paris, France
| | - J Soulier
- University Paris Diderot, INSERM U944 Saint-Louis Hospital, Department of Hematology, Paris, France
| | - C Preudhomme
- CHU Lille University Hospital, Department of Hematology, Lille, France
| | - M H Cheok
- INSERM UMR-S1172, Institute for Cancer Research of Lille, Factors of Leukemia Cell Persistance, Lille Cedex, France
| |
Collapse
|
24
|
Rouers M, Dubourg S, Bornert F, Truntzer P, Antoni D, Couchot J, Ganansia V, Bourrier C, Guihard S, Noël G. État buccodentaire des patients avant radiothérapie des voies aérodigestives supérieures : analyse prospective de 48 patients. Cancer Radiother 2016; 20:199-204. [PMID: 27131393 DOI: 10.1016/j.canrad.2015.12.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Revised: 12/12/2015] [Accepted: 12/16/2015] [Indexed: 12/21/2022]
Affiliation(s)
- M Rouers
- Faculté de chirurgie dentaire de Strasbourg, 8, rue Sainte-Élisabeth, 67000 Strasbourg, France
| | - S Dubourg
- Faculté de chirurgie dentaire de Strasbourg, 8, rue Sainte-Élisabeth, 67000 Strasbourg, France; Unité de pathologie-chirurgie buccale, pôle de médecine et de chirurgie buccodentaires, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France
| | - F Bornert
- Faculté de chirurgie dentaire de Strasbourg, 8, rue Sainte-Élisabeth, 67000 Strasbourg, France; Unité de pathologie-chirurgie buccale, pôle de médecine et de chirurgie buccodentaires, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France
| | - P Truntzer
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - D Antoni
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France; Fédération de médecine translationnelle de Strasbourg (FMTS), laboratoire EA 3430, université de Strasbourg, 67065 Strasbourg, France
| | - J Couchot
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - V Ganansia
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - C Bourrier
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - S Guihard
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | - G Noël
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France; Fédération de médecine translationnelle de Strasbourg (FMTS), laboratoire EA 3430, université de Strasbourg, 67065 Strasbourg, France.
| |
Collapse
|
25
|
Poret N, Fu Q, Guihard S, Cheok M, Miller K, Zeng G, Quesnel B, Troussard X, Galiègue-Zouitina S, Shelley CS. CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy. Cancer Res 2016; 75:3902-11. [PMID: 26170397 DOI: 10.1158/0008-5472.can-15-0893] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Hairy cell leukemia (HCL) is characterized by underexpression of the intracellular signaling molecule RhoH. Reconstitution of RhoH expression limits HCL pathogenesis in a mouse model, indicating this could represent a new therapeutic strategy. However, while RhoH reconstitution is theoretically possible as a therapy, it is technically immensely challenging as an appropriately functional RhoH protein needs to be specifically targeted. Because of this problem, we sought to identify druggable proteins on the HCL surface that were dependent upon RhoH underexpression. One such protein was identified as CD38. Analysis of 51 HCL patients demonstrated that 18 were CD38-positive. Interrogation of the clinical record of 23 relapsed HCL patients demonstrated those that were CD38-positive had a mean time to salvage therapy 71 months shorter than patients who were CD38-negative. Knockout of the CD38 gene in HCL cells increased apoptosis, inhibited adherence to endothelial monolayers, and compromised ability to produce tumors in vivo. Furthermore, an anti-CD38 antibody proved effective against pre-existing HCL tumors. Taken together, our data indicate that CD38 expression in HCL drives poor prognosis by promoting survival and heterotypic adhesion. Our data also indicate that CD38-positive HCL patients might benefit from treatments based on CD38 targeting.
Collapse
Affiliation(s)
- Nicolas Poret
- Institut National de la Santé et de la Recherche Medicale UMR-S1172, Centre Jean-Pierre Aubert, Institut pour la Recherche sur le Cancer de Lille and Université de Lille, Lille, France
| | - Qiangwei Fu
- Kabara Cancer Research Institute, Gundersen Medical Foundation, La Crosse, Wisconsin
| | - Soizic Guihard
- Institut National de la Santé et de la Recherche Medicale UMR-S1172, Centre Jean-Pierre Aubert, Institut pour la Recherche sur le Cancer de Lille and Université de Lille, Lille, France
| | - Meyling Cheok
- Institut National de la Santé et de la Recherche Medicale UMR-S1172, Centre Jean-Pierre Aubert, Institut pour la Recherche sur le Cancer de Lille and Université de Lille, Lille, France
| | - Katie Miller
- Department of Biology, Saint Mary's University of Minnesota, Winona, Minnesota
| | - Gordon Zeng
- Department of Pathology, Gundersen Health System, La Crosse, Wisconsin
| | - Bruno Quesnel
- Institut National de la Santé et de la Recherche Medicale UMR-S1172, Centre Jean-Pierre Aubert, Institut pour la Recherche sur le Cancer de Lille and Université de Lille, Lille, France. Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Xavier Troussard
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Caen, Caen, France
| | - Sylvie Galiègue-Zouitina
- Institut National de la Santé et de la Recherche Medicale UMR-S1172, Centre Jean-Pierre Aubert, Institut pour la Recherche sur le Cancer de Lille and Université de Lille, Lille, France.
| | - Carl Simon Shelley
- Kabara Cancer Research Institute, Gundersen Medical Foundation, La Crosse, Wisconsin.
| |
Collapse
|
26
|
Rouers M, Truntzer P, Dubourg S, Guihard S, Antoni D, Noël G. État dentaire des patients atteints d’un cancer des voies aérodigestives supérieures. Cancer Radiother 2015. [DOI: 10.1016/j.canrad.2015.03.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
27
|
Marceau-Renaut A, Guihard S, Castaigne S, Dombret H, Preudhomme C, Cheok M. Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations. Am J Hematol 2015; 90:E93-4. [PMID: 25611491 DOI: 10.1002/ajh.23949] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2015] [Accepted: 01/14/2015] [Indexed: 11/11/2022]
Affiliation(s)
- Alice Marceau-Renaut
- U837, INSERM; Lille France
- Hematology Laboratory; Biology and Pathology Center, Lille University Hospital; Lille France
| | | | | | - Hervé Dombret
- ALFA Cooperative Group; Saint-Louis Hospital; Paris France
| | - Claude Preudhomme
- U837, INSERM; Lille France
- Hematology Laboratory; Biology and Pathology Center, Lille University Hospital; Lille France
| | | |
Collapse
|
28
|
Burgy M, Barthélémy P, Dupret-Bories A, Truntzer P, Korenbaum C, Meyer N, Flesch H, Bronner G, Heitz D, Nehme H, Guihard S, Hemar P, Borel C. Cetuximab plus platinum-based chemotherapy in elderly patients with recurrent or metastatic head and neck squamous cell carcinoma: A French experience from a single institution. J Geriatr Oncol 2014. [DOI: 10.1016/j.jgo.2014.09.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
29
|
Clavier J, Antoni D, Bauer N, Guillerme F, Truntzer P, Atlani D, Guihard S, Lahlou A, Pop M, Thiriat S, Vigneron C, Poulin N, Noël G. Delineation of Brain Metastases for Stereotactic Radiation Therapy: An Interobserver Contour Comparison. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Keller A, Clavier J, Waisse W, Vigneron C, Bauer N, Antoni D, Truntzer P, Guihard S, Schumacher C, Pop M, Salze P, Noël G. Peut-on se passer de l’imagerie multimodalités dans la délinéation du lit opératoire des métastases cérébrales ? Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
31
|
Abstract
The use of combination chemotherapy to cure acute lymphoblastic leukemia in children and acute myeloid leukemia in adults emerged for acute myeloid leukemia in the 1960s and for acute lymphoblastic leukemia in the 1980s as a paradigm for curing any disseminated cancer. This article summarizes recent developments and considerations in the use of acute leukemia xenografts established in immunodeficient mice to elucidate the genetic and genomic basis of acute leukemia pathogenesis and treatment response.
Collapse
Affiliation(s)
- Soizic Guihard
- Jean-Pierre Aubert Research Center, INSERM U837, Institute for Cancer Research, 1 Place de Verdun, F-59045 Lille Cedex, France
| | | | | |
Collapse
|
32
|
Jaussaud S, Guihard S, Niederst C, Borel C, Meyer P, Hémar P, Schultz P, Noël G, Féki A. [Constraints of the dentist are consistent with the results of an optimal irradiation with modulated intensity in N0 oropharyngeal cancer]. Cancer Radiother 2013; 17:265-71. [PMID: 23726044 DOI: 10.1016/j.canrad.2013.01.020] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2012] [Revised: 12/26/2012] [Accepted: 01/31/2013] [Indexed: 10/26/2022]
Abstract
PURPOSE We compared intensity-modulated radiotherapy and 3D-conformal irradiation in oropharyngeal cancers according to the requirement of dentists. MATERIAL AND METHODS From the files of seven patients with cancer of the oropharynx, two dosimetry plannings for 3D-conformal radiotherapy and intensity-modulated radiotherapy with tomotherapy were performed. The dose distributions in the target volumes and organs at risk in relation to the dental sphere were compared. RESULTS For the planning target volume of the primitive tumour sites, average values of V95%, D2%, D98% and of the conformal index were statistically in favour of tomotherapy. For the planning target volume of node areas, averages values of V95%, D2%, D98% were statistically in favour of tomotherapy. For ipsi- and controlateral parotide glands, average values of V15Gy, V26Gy, V30Gy, V40Gy were significantly lower for tomotherapy. For the submaxillary glands, average values of mean doses and V40Gy were statistically in favour of tomotherapy. For the buccal cavity, the average values of V45Gy were statistically in favour of tomotherapy. For ipsi- and controlateral masseter muscles, the average values of mean doses were statistically in favour of tomotherapy. For the ipsi- and controlateral temporomandibular joints, average values of mean doses and V60Gy were statistically in favour of tomotherapy. For mandibular bone, average values of mean doses and V40Gy, V50Gy, V60Gy and V70Gy were statistically in favour of tomotherapy. For maxillary bone, average values of V40Gy, V50Gy and V60Gy were statistically in favour of tomotherapy. CONCLUSION The radiation oncologist can constrain the intensity-modulated radiotherapy dosimetry to the needs of dentists to prevent or improve dental care and quality of life.
Collapse
Affiliation(s)
- S Jaussaud
- Faculté Dentaire, Hôpital Civil, 67000 Strasbourg, France
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Peyrouze P, Guihard S, Grardel N, Berthon C, Pottier N, Pigneux A, Cahn JY, Béné MC, Lhéritier V, Delabesse E, Macintyre E, Thomas X, Dombret H, Ifrah N, Cheok M. Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study. Br J Haematol 2012; 159:599-602. [PMID: 23016962 DOI: 10.1111/bjh.12063] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2012] [Accepted: 08/27/2012] [Indexed: 11/28/2022]
|
34
|
Noël G, Bauer N, Clavier JB, Guihard S, Lim O, Jastaniah Z. [Stereotactic radiotherapy of intracranial benign tumors]. Cancer Radiother 2012; 16:410-7. [PMID: 22921979 DOI: 10.1016/j.canrad.2012.07.179] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2012] [Revised: 06/22/2012] [Accepted: 07/05/2012] [Indexed: 11/25/2022]
Abstract
Stereotactic radiotherapy can be delivered in one fraction or in multiple fractions schedule. It is used in benign tumours such as meningiomas, mainly localized in the base of the skull, for acoustic schwannoma and pituitary tumours. Whatever the tumour, results with the Gamma Knife(®) are the most numerous, but those obtained by linear accelerators, adapted or dedicated, are comparable. The peripheral dose is preferred to the dose delivered to the isocentre. One fraction stereotactic irradiation should be proposed in small lesions and fractionated treatment for tumours larger. Whatever the tumour, the results are satisfactory with a control rate of 90%. However, this value reflects a disparity assessment, radiological stability for meningiomas, radiological stability and preservation of useful hearing in schwannoma and radiological stability and a decrease in hormonal secretions for pituitary adenomas. Overall complication rates are low. In total, the treatment of benign lesions with stereotactic irradiation gives satisfactory results with few complications.
Collapse
Affiliation(s)
- G Noël
- Département universitaire de radiothérapie, centre de lutte contre le cancer Paul-Strauss, Strasbourg, France.
| | | | | | | | | | | |
Collapse
|
35
|
Jung A, Guihard S, Ledrappier S, Brochot A, Dalstein V, de Reynies A, Wasylyk B, Clavel C, Noel G, Abecassis J. 770 An Increased CD8+ Cytotoxic T Cell Immune Response in Human Papillomavirus-related Oropharyngeal Carcinoma Correlates With Patients' Improved Prognosis. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71406-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Guihard S, Jung AC, Noël G. [High-risk human papilloma virus associated oropharynx squamous cell carcinomas: clinical, biological implications and therapeutical perspectives]. Cancer Radiother 2012; 16:34-43. [PMID: 22316562 DOI: 10.1016/j.canrad.2011.11.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2011] [Revised: 11/24/2011] [Accepted: 11/29/2011] [Indexed: 12/19/2022]
Abstract
The infection of the head and neck epithelium by high-risk human papillomaviruses (HPV) is a risk factor for cancer onset and development. The incidence of HPV-related head and neck squamous cell carcinoma is currently increasing. These lesions display distinct clinical features. HPV positive patients are often younger and have a smaller history of tobacco smoking and alcohol drinking, but have a history of virus-transmitting sex practices. HPV-related tumours are mainly found in the oropharynx, are more associated to a local lymph node invasion and display a poorly differentiated morphology. Despite these more aggressive features, HPV-positive head and neck squamous cell carcinomas correlate with an improved local control, disease-free and global survival. It is thought that HPV-driven specific biologic abnormalities underlie higher tumour sensitivity to chemotherapeutic drugs and ionizing radiations. The expression of the HPV E6 and E7 oncoproteins induce cell transformation by interfering with cell signalling pathways involved in apoptosis, cell cycle, angiogenesis and induce the overexpression of the CDKN2A gene. Therefore, alternative treatments based on therapies targeting these pathways in combination with radiation dose de-escalation could be proposed to HPV-positive patients, if they are properly and reliably identified.
Collapse
Affiliation(s)
- S Guihard
- Département de radiothérapie, centre de lutte contre le cancer Paul-Strauss, BP 42, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg cedex, France
| | | | | |
Collapse
|
37
|
Saulnier N, Guihard S, Holy X, Decembre E, Jurdic P, Clay D, Feuillet V, Pagès G, Pouysségur J, Porteu F, Gaudry M. ERK1 regulates the hematopoietic stem cell niches. PLoS One 2012; 7:e30788. [PMID: 22303456 PMCID: PMC3268766 DOI: 10.1371/journal.pone.0030788] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2011] [Accepted: 12/29/2011] [Indexed: 11/18/2022] Open
Abstract
The mitogen-activated protein kinases (MAPK) ERK1 and ERK2 are among the major signal transduction molecules but little is known about their specific functions in vivo. ERK activity is provided by two isoforms, ERK1 and ERK2, which are ubiquitously expressed and share activators and substrates. However, there are not in vivo studies which have reported a role for ERK1 or ERK2 in HSCs and the bone marrow microenvironment. The present study shows that the ERK1-deficient mice present a mild osteopetrosis phenotype. The lodging and the homing abilities of the ERK1(-/-) HSC are impaired, suggesting that the ERK1(-/-)-defective environment may affect the engrafment of HSCs. Serial transplantations demonstrate that ERK1 is involved in the maintenance of an appropriate medullar microenvironment, but that the intrinsic properties of HSCs are not altered by the ERK1(-/-) defective microenvironment. Deletion of ERK1 impaired in vitro and in vivo osteoclastogenesis while osteoblasts were unaffected. As osteoclasts derive from precursors of the monocyte/macrophage lineage, investigation of the monocytic compartment was performed. In vivo analysis of the myeloid lineage progenitors revealed that the frequency of CMPs increased by approximately 1.3-fold, while the frequency of GMPs significantly decreased by almost 2-fold, compared with the respective WT compartments. The overall mononuclear-phagocyte lineage development was compromised in these mice due to a reduced expression of the M-CSF receptor on myeloid progenitors. These results show that the cellular targets of ERK1 are M-CSFR-responsive cells, upstream to osteoclasts. While ERK1 is well known to be activated by M-CSF, the present results are the first to point out an ERK1-dependent M-CSFR regulation on hematopoietic progenitors. This study reinforces the hypothesis of an active cross-talk between HSCs, their progeny and bone cells in the maintenance of the homeostasis of these compartments.
Collapse
Affiliation(s)
- Nathalie Saulnier
- Institut Cochin, Université Paris Descartes, Sorbonne Paris Descartes, CNRS (UMR 8104), Paris, France
- Inserm U1016, Paris, France
| | - Soizic Guihard
- Institut Cochin, Université Paris Descartes, Sorbonne Paris Descartes, CNRS (UMR 8104), Paris, France
- Inserm U1016, Paris, France
| | - Xavier Holy
- Service histologie et réparation tissulaire, IRBA/IMASSA, Brétigny-sur-Orge, France
| | - Elodie Decembre
- Institut de Génomique Fonctionnelle de Lyon, Université de Lyon, Université Lyon 1, CNRS, INRA, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Pierre Jurdic
- Institut de Génomique Fonctionnelle de Lyon, Université de Lyon, Université Lyon 1, CNRS, INRA, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Denis Clay
- Inserm U972, Institut André Lwoff, Hôpital Paul Brousse, Villejuif, France
| | - Vincent Feuillet
- Institut Cochin, Université Paris Descartes, Sorbonne Paris Descartes, CNRS (UMR 8104), Paris, France
- Inserm U1016, Paris, France
| | - Gilles Pagès
- Institut de recherche Signalisation, Biologie du Développement et Cancer, Université de Nice, France
| | - Jacques Pouysségur
- Institut de recherche Signalisation, Biologie du Développement et Cancer, Université de Nice, France
| | - Françoise Porteu
- Institut Cochin, Université Paris Descartes, Sorbonne Paris Descartes, CNRS (UMR 8104), Paris, France
- Inserm U1016, Paris, France
| | - Murielle Gaudry
- Institut Cochin, Université Paris Descartes, Sorbonne Paris Descartes, CNRS (UMR 8104), Paris, France
- Inserm U1016, Paris, France
- * E-mail:
| |
Collapse
|
38
|
Antoni D, Clavier JB, Guihard S, Schumacher C, Pop M, Benoît C, Noël G. Rôle de la chirurgie et de la radiothérapie postopératoire chez les patients atteints d’une ou deux métastases cérébrales et de groupe I ou II de la classification Recursive Partitioning Analysis. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
39
|
Guihard S, Jung AC, Abécassis J, Clavier JB, Bauer N, Flesch H, Bronner G, Noël G. Valeurs pronostiques de l’expression du transcrit viral de E6/E7 et de la surexpression de CDKN2A dans une série rétrospective de 144 patients traités pour une tumeur oropharyngée. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
40
|
Clavier JB, Guihard S, Atlani D, Antoni D, Guillerme F, Noël G. Étude rétrospective comparant les doses de 66 et 50Gy dans le cadre d’une chimioradiothérapie exclusive pour cancer de l’œsophage. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
41
|
Guihard S, Jung A, Abecassis J, Clavier J, Bauer N, Flesch H, Bronner G, Noel G. Prognostic Value Of HPV E6/E7 mRNA Expression In A Retrospective Series Of 144 French Patients. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
42
|
Guillerme F, Kurtz J, Clavier J, Guihard S, Schumacher C, Jung G, Brigand C, Meyer C, Rohr S, Noël G. Comparison of Hypofractionated and Conventional Preoperative Radiotherapy for Locally Advanced Rectal Cancer in the Elderly. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
43
|
Antoni D, Clavier J, Benolt C, Pop M, Schumacher C, Guihard S, Noel G. 8728 POSTER Role of Surgery and Postoperative Radiotherapy for Patients RPA I or II With 1 or 2 Brain Metastases. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72279-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
44
|
Guihard S, Altmeyer A, Ramolu L, Macabre C, Abécassis J, Noël G, Jung A. Analyse du rôle du gène codant l’Amyloid-Precursor Protein Binding Protein 1 (APP-BP1) dans la radiosensibilité des carcinomes épidermoïdes des voies aérodigestives supérieures infectées par le papillomavirus humain. Cancer Radiother 2010. [DOI: 10.1016/j.canrad.2010.07.580] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Foretz M, Hébrard S, Guihard S, Leclerc J, Do Cruzeiro M, Hamard G, Niedergang F, Gaudry M, Viollet B. The AMPKγ1 subunit plays an essential role in erythrocyte membrane elasticity, and its genetic inactivation induces splenomegaly and anemia. FASEB J 2010; 25:337-47. [PMID: 20881209 DOI: 10.1096/fj.10-169383] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
AMP-activated protein kinase (AMPK) is an αβγ heterotrimer conserved throughout evolution and important for energy sensing in all eukaryote cells. AMPK controls metabolism and various cellular events in response to both hormones and changes in cellular energy status. The γ subunit senses intracellular energy status through the competitive binding of AMP and ATP. We show here that targeted disruption of the mouse AMPKγ1 gene (Prkag1) causes regenerative hemolytic anemia by increasing the sequestration of abnormal erythrocytes. Prkag1(-/-) mice displayed splenomegaly and iron accumulation due to compensatory splenic erythropoiesis and erythrophagocytosis. Moreover, AMPKγ1-deficient erythrocytes were highly resistant to osmotic hemolysis and poorly deformable in response to increasing shear stress, consistent with greater membrane rigidity. No change in cytoskeletal protein composition was observed; however, the phosphorylation level of adducin, a protein promoting the binding of spectrin to actin, was higher in AMPKγ1-deficient erythrocytes. Together, these results demonstrate that AMPKγ1 subunit is required for the maintenance of erythrocyte membrane elasticity.
Collapse
Affiliation(s)
- Marc Foretz
- Institut Cochin, Département d'Endocrinologie Métabolisme et Cancer, 24 rue du Faubourg St.-Jacques, 75014 Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Foretz M, Guihard S, Leclerc J, Fauveau V, Couty JP, Andris F, Gaudry M, Andreelli F, Vaulont S, Viollet B. Maintenance of red blood cell integrity by AMP-activated protein kinase alpha1 catalytic subunit. FEBS Lett 2010; 584:3667-71. [PMID: 20670625 DOI: 10.1016/j.febslet.2010.07.041] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2010] [Revised: 07/20/2010] [Accepted: 07/22/2010] [Indexed: 10/19/2022]
Abstract
AMP-activated protein kinase (AMPK) plays a pivotal role in regulating cellular energy metabolism. We previously showed that AMPKalpha1-/- mice develop moderate anemia associated with splenomegaly and high reticulocytosis. Here, we report that splenectomy of AMPKalpha1-/- mice worsened anemia supporting evidence that AMPKalpha1-/- mice developed a compensatory response through extramedullary erythropoiesis in the spleen. Transplantation of bone marrow from AMPKalpha1-/- mice into wild-type recipients recapitulated the hematologic phenotype. Further, AMPKalpha1-/- red blood cells (RBC) showed less deformability in response to shear stress limiting their membrane flexibility. Thus, our results highlight the crucial role of AMPK to preserve RBC integrity.
Collapse
Affiliation(s)
- Marc Foretz
- Institut Cochin, Université Paris Descartes, Centre National de la Recherche Scientifique (UMR8104), Paris, France; INSERM, U1016, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Jung A, Guihard S, Altmeyer A, Ramolu L, Macabre C, Noël G, Abecassis J. 854 The Amyloid Beta Precursor Protein-Binding Protein 1 (APP-BP1) encoding gene is involved in the radiosensitivity of the Human Papillomavirus (HPV)-positive SCC90 oropharyngeal cell line. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71648-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
48
|
Pawlikowska P, Leray I, de Laval B, Guihard S, Kumar R, Rosselli F, Porteu F. ATM-dependent expression of IEX-1 controls nuclear accumulation of Mcl-1 and the DNA damage response. Cell Death Differ 2010; 17:1739-50. [PMID: 20467439 DOI: 10.1038/cdd.2010.56] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
The early-response gene product IEX-1 (also known as IER3) was recently found to interact with the anti-apoptotic Bcl-2 family member, myeloid cell leukemia-1 (Mcl-1). In this study we show that this interaction specifically and timely controls the accumulation of Mcl-1 in the nucleus in response to DNA damage. The IEX-1 protein is rapidly induced by γ-irradiation, genotoxic agents or replication inhibitors, in a way dependent on ataxia telangiectasia mutated (ATM) activity and is necessary for Mcl-1 nuclear translocation. Conversely, IEX-1 protein proteasomal degradation triggers the return of Mcl-1 to the cytosol. IEX-1 and Mcl-1 are integral components of the DNA damage response. Loss of IEX-1 or Mcl-1 leads to genomic instability and increased sensitivity to genotoxic and replicative stresses. The two proteins cooperate to maintain Chk1 activation and G2 checkpoint arrest. Mcl-1 nuclear translocation may foster checkpoint and improve the tumor resistance to DNA damage-based cancer therapies. Deciphering the pathways involved in IEX-1 degradation should lead to the discovery of new therapeutic targets to increase sensitivity of tumor cells to chemotherapy.
Collapse
|
49
|
Guihard S, Noël G. Les tumeurs à cellules de Merkel, rôle de la radiothérapie. Analyse de la littérature. Cancer Radiother 2009; 13:47-54. [DOI: 10.1016/j.canrad.2008.06.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2008] [Revised: 06/17/2008] [Accepted: 06/24/2008] [Indexed: 11/30/2022]
|